У нас вы можете посмотреть бесплатно Recent Highlights in Targeted Protein Degradation или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this Drug Hunter Flash Talk, we discuss scientific highlights from small molecules that induce the degradation of their targets of interest, with a focus on molecules that have recently demonstrated important proofs-of-concept in the clinic. The talk covers: -Theoretical advantages of targeted protein degradation over traditional small molecules -Recent highlights throughout the industry illustrating these advantages -Areas to watch in targeted protein degradation on the horizon -Some of the highlights mentioned in the talk include: -9:00: Ten ways degraders can differentiate in theory -14:47: Agnostic to ligand mode of action: AR degraders -16:18: AR degraders and ER degraders from Arvinas (bavdegalutamide/ARV-110, ARV-766, and ARV-471) -18:58: MDM2 degraders from Kymera (e.g. KT-253) -20:30: BRAF and allosteric EGFR degraders from C4 and Roche (e.g. CFT1946, CFT8919) -21:43: IRAK4 degraders from Kymera (e.g. KT-474) -22:54: BRD9 and BRM/BRG1 degraders from C4 Therapeutics and Prelude Therapeutics -24:41: BTK degraders from Nurix (e.g. NX-2127, NX-5948) -26:24: IV STAT3 degraders from Kymera Therapeutics (e.g. KT-333 and KT-003) -27:45: RIPK2 degraders from GSK and PCSK9 degraders from Merck -28:55: EGFR L858R degrader from Roche and C4 (e.g. compound 144) -30:32: PCSK9 degrader from Merck (e.g. compound 16) -32:17: A tissue-selective Bcl-XL degrader from Dialectic Therapeutics (e.g. DT2216) -33:31: BRAF degrader from C4 Therapeutics (e.g. CFT1946) -35:00: Brain-penetrant degraders -36:20: A cyclin D1 degrader from Mt. Sinai (e.g. MS28) 37:38:Ten ways degraders can differentiate in theory -38:22: Areas to watch in targeted protein degradation on the horizon: Presented by: Dennis Hu, CEO & Editor-in-Chief, Drug Hunter with co-host Pierre Morieux, Chemistry Product Marketing Manager, Revvity Signals. Presented on June 28, 2023, as part of the Drug Hunter Flash Talk series. Sign up for future sessions here: https://lu.ma/w1q906iz